CL2010001618A1 - Compounds derived from oxazolidinone substituted with a cyclic amidoxime or cyclic amidrazone group, factor xa inhibitors; pharmaceutical composition; and its use to prevent or treat thrombosis, myocardial infarction, arteriosclerosis, among other diseases. - Google Patents

Compounds derived from oxazolidinone substituted with a cyclic amidoxime or cyclic amidrazone group, factor xa inhibitors; pharmaceutical composition; and its use to prevent or treat thrombosis, myocardial infarction, arteriosclerosis, among other diseases.

Info

Publication number
CL2010001618A1
CL2010001618A1 CL2010001618A CL2010001618A CL2010001618A1 CL 2010001618 A1 CL2010001618 A1 CL 2010001618A1 CL 2010001618 A CL2010001618 A CL 2010001618A CL 2010001618 A CL2010001618 A CL 2010001618A CL 2010001618 A1 CL2010001618 A1 CL 2010001618A1
Authority
CL
Chile
Prior art keywords
cyclic
pharmaceutical composition
factor
arteriosclerosis
inhibitors
Prior art date
Application number
CL2010001618A
Other languages
Spanish (es)
Inventor
Ho Young Song
Dae Yon Lee
Hee Sock Park
Sung Yoon Baek
Sang Eun Chae
Sang Hui Jo
Yeon Ok Kim
Hyang Sook Lee
Ju Hyun Park
Tan Kyo Park
Sung Ho Woo
Young Zu Kim
Young Lag Cho
Original Assignee
Legochem Bioscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Legochem Bioscience Ltd filed Critical Legochem Bioscience Ltd
Publication of CL2010001618A1 publication Critical patent/CL2010001618A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DERIVADOS DE OXAZOLIDINONA SUSTITUIDA CON UN GRUPO AMIDOXIMA CICLICA O AMIDRAZONA CÍCLICA Y SUS SALES ACEPTADAS PARA USO FARMACÉUTICO, DONDE A ES UN RESIDUO SELECCIONADO  (FIGURA 1) INHIBIDORES DEL FACTOR XA; COMPOSICIÓN FARMACÉUTICA QUE LOS CONTIENEN; Y SU USO EN EL TRATAMIENTO Y PREVENCION DE LA TROMBOEMBOLIA, TUMORES Y COMO ANTICOAGULANTES.  THE PRESENT INVENTION REFERS TO COMPOUNDS DERIVED FROM OXAZOLIDINONE SUBSTITUTED WITH A CYCLIC AMIDOXIMA OR CYCLIC AMIDRAZONE GROUP AND ITS ACCEPTED SALTS FOR PHARMACEUTICAL USE, WHERE A IS A SELECTED RESIDUE (FIGURE 1) INHIBITOR FACTOR. PHARMACEUTICAL COMPOSITION CONTAINING THEM; AND ITS USE IN THE TREATMENT AND PREVENTION OF THROMBOEMBOLIA, TUMORS AND AS ANTICOAGULANTS.

CL2010001618A 2008-07-03 2010-12-29 Compounds derived from oxazolidinone substituted with a cyclic amidoxime or cyclic amidrazone group, factor xa inhibitors; pharmaceutical composition; and its use to prevent or treat thrombosis, myocardial infarction, arteriosclerosis, among other diseases. CL2010001618A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020080064178A KR100898361B1 (en) 2008-07-03 2008-07-03 Fxa inhibitors with cyclic amidoxime or cyclic amidrazone as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof

Publications (1)

Publication Number Publication Date
CL2010001618A1 true CL2010001618A1 (en) 2011-10-28

Family

ID=40862256

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2010001618A CL2010001618A1 (en) 2008-07-03 2010-12-29 Compounds derived from oxazolidinone substituted with a cyclic amidoxime or cyclic amidrazone group, factor xa inhibitors; pharmaceutical composition; and its use to prevent or treat thrombosis, myocardial infarction, arteriosclerosis, among other diseases.

Country Status (17)

Country Link
US (1) US8178525B2 (en)
EP (1) EP2307407B1 (en)
JP (1) JP5325289B2 (en)
KR (1) KR100898361B1 (en)
CN (1) CN102083825B (en)
AU (1) AU2009266631B2 (en)
BR (1) BRPI0915326B8 (en)
CA (1) CA2728350C (en)
CL (1) CL2010001618A1 (en)
ES (1) ES2566755T3 (en)
IL (1) IL210384A (en)
MX (1) MX2010013969A (en)
MY (1) MY165573A (en)
NZ (1) NZ590315A (en)
RU (1) RU2468024C2 (en)
UA (1) UA97598C2 (en)
WO (1) WO2010002115A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101023174B1 (en) * 2008-09-24 2011-03-18 주식회사 레고켐 바이오사이언스 Novel Oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone and Pharmaceutical Compositions thereof
KR101037052B1 (en) * 2009-07-08 2011-05-26 주식회사 레고켐 바이오사이언스 Method for preparing 5-chloro-N-5S-2-oxo-3-4-5,6-dihydro-1,2,4-triazin-14H-ylphenyl-1,3-oxazolidin-5-ylmethylthiophen-2-carboxamide derivatives, and their intermediates
KR101037051B1 (en) 2009-07-08 2011-05-26 주식회사 레고켐 바이오사이언스 Method for preparing of S-5-chloro-N-3-4-5,6-dihydro-4H-1,2,4-oxadiazin-3-ylphenyl-2-oxooxazolidin-5-ylmethylthiophene-2-carboxamide derivatives
JP6325978B2 (en) * 2011-05-06 2018-05-16 エギシュ ヂョヂセルヂャール ザートケルエン ミケデ レースヴェーニタールササーグ Process for the preparation of rivaroxaban and intermediates formed in the process
US8877628B2 (en) 2012-07-12 2014-11-04 Micron Technologies, Inc. Methods of forming nano-scale pores, nano-scale electrical contacts, and memory devices including nano-scale electrical contacts, and related structures and devices
RU2663617C1 (en) * 2014-07-18 2018-08-07 Грин Кросс Корпорейшн Novel crystalline form of 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulphonate and pharmaceutical composition containing same
CN114591337A (en) * 2022-03-31 2022-06-07 武汉工程大学 Pyrazolo [1,2-a ] [1,2,4] triazine-3, 6-dione derivative and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (en) * 1999-12-24 2001-07-05 Bayer Ag Substituted oxazolidinones and their use
DE10129725A1 (en) * 2001-06-20 2003-01-02 Bayer Ag Combination therapy of substituted oxazolidinones
DE10342570A1 (en) 2003-09-15 2005-04-14 Bayer Healthcare Ag Process for the preparation of 4- (4-aminophenyl) -3-morpholinone
US20080051578A1 (en) * 2006-08-24 2008-02-28 Georg Dahmann Substituted biaryls, process for their manufacture and use thereof as medicaments
WO2008140220A1 (en) * 2007-05-09 2008-11-20 Legochem Bioscience Ltd. Fxa inhibitors with cyclic amidines as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof

Also Published As

Publication number Publication date
IL210384A0 (en) 2011-03-31
WO2010002115A2 (en) 2010-01-07
MY165573A (en) 2018-04-05
UA97598C2 (en) 2012-02-27
BRPI0915326B8 (en) 2021-05-25
JP5325289B2 (en) 2013-10-23
AU2009266631B2 (en) 2012-03-15
US8178525B2 (en) 2012-05-15
EP2307407B1 (en) 2016-03-16
CA2728350C (en) 2013-09-24
BRPI0915326A2 (en) 2015-08-04
JP2011526624A (en) 2011-10-13
MX2010013969A (en) 2011-05-02
WO2010002115A3 (en) 2010-03-11
RU2011103766A (en) 2012-08-10
CN102083825B (en) 2014-07-30
ES2566755T3 (en) 2016-04-15
NZ590315A (en) 2012-11-30
CN102083825A (en) 2011-06-01
CA2728350A1 (en) 2010-01-07
RU2468024C2 (en) 2012-11-27
EP2307407A4 (en) 2011-08-24
BRPI0915326B1 (en) 2021-04-06
KR100898361B1 (en) 2009-05-20
EP2307407A2 (en) 2011-04-13
AU2009266631A1 (en) 2010-01-07
US20110112083A1 (en) 2011-05-12
IL210384A (en) 2014-09-30

Similar Documents

Publication Publication Date Title
CL2010001618A1 (en) Compounds derived from oxazolidinone substituted with a cyclic amidoxime or cyclic amidrazone group, factor xa inhibitors; pharmaceutical composition; and its use to prevent or treat thrombosis, myocardial infarction, arteriosclerosis, among other diseases.
PE20191541A1 (en) COMPOSITIONS AND METHODS TO INHIBIT THE ACTION OF ARGINASE
AR120700A1 (en) KRAS G12C INHIBITORS
PA8848201A1 (en) AMINOTETRAHYDROPIRANS AS INHIBITORS OF DIPEPTIDIL PEPTIDASA-IV FOR THE TREATMENT OR PREVENTION OF DIABETES
ECSP077980A (en) AKT ACTIVITY INHIBITORS
CR20110224A (en) PIRAZOLOPIRIMIDINA INHIBITOR JAK COMPOUNDS AND METHODS
CL2009001059A1 (en) Compounds derived from substituted 1,3-oxazin-2-one-3.6, inhibitors of the activity of 11-beta-hydroxysteroid dehydrogenase i; pharmaceutical composition that includes them; Useful in the treatment of diseases such as diabetes mellitus, among others.
CL2009000316A1 (en) Compounds derived from benzomorphane urea and their salts, inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase; preparation procedure; pharmaceutical composition; and use for the treatment or prevention of metabolic disorders.
CL2012000033A1 (en) Compounds n- (3- (4as, 7as) -2-amino-4a, 5,7,7a-tetrahydro-4h-furo [3,4-d] [1,3] thiazin-7a-yl) -4- fluorophenyl) -5-fluoropiconylamide, bace inhibitor; pharmaceutical composition comprising them, use of the compound for the treatment of Alzheimer's disease.
CU20100229A7 (en) TRIAZINE COMPOUNDS AS MTOR AND QUINASA INHIBITORS P13
AR070479A1 (en) FUSIONED HETEROCICLIC DERIVATIVE AND ITS USE
ECSP088765A (en) AMINOTETRAHYDROPIRANS AS INHIBITORS OF DIPEPTIDIL PEPTIDASA-IV FOR THE TREATMENT OR PREVENTION OF DIABETES
ECSP088221A (en) ALFA2C ADRENORECEPTORS AGONISTS
AR059066A1 (en) COMBINATIONS OF THE ANGIOPOYETINE INHIBITOR -2 (ANG2) AND THE VASCULAR ENDOTELIAL GROWTH FACTOR INHIBITOR (VEGF)
CL2011000159A1 (en) Compounds derived from 1,3-oxazin-2-one, 11beta-hsd1 inhibitors; pharmaceutical composition that includes them; and its use in the treatment of diabetes.
CL2008001743A1 (en) Use of a compound derived from quinazoline to treat cancer; use of the compound and another antineoplastic compound; quinazoline derived compounds; and pharmaceutical composition comprising them.
CL2008002430A1 (en) Benzenesulfonamide derived compounds, cathepsin c inhibitors; pharmaceutical composition comprising them; and its use for the treatment of copd.
CL2008000202A1 (en) Compounds derived from n-aryl-acetamide, trpv1 antagonist, pharmaceutical composition that comprises them, useful in the treatment of pain.
AR056860A1 (en) TRIAZOL DERIVATIVES INHIBITORS OF QUINASA TGF-BETA1 RECEPTORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES FOR TUMOR TREATMENT
AR083417A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING AN INHIBITOR DGAT1
AR078278A1 (en) ANTAGONISTS OF TIAZOL AND OXAZOL HEPCIDINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME FOR THE TREATMENT OF ANEMIAS AND ILLNESSES ASSOCIATED WITH IRON DEFICIENCIES.
AR077080A1 (en) COMPOUNDS OF 2,3-DIHIDRO-1H-INDENO
CO6270285A2 (en) DERIVATIVES OF 4 - [(4-AMINO-1, 3, 5-TRIAZIN-2-IL) AMINO] -N-ARILMETILCICLOALQUILCARBOXAMIDA
CL2011001093A1 (en) Compounds derived from 4- [2- (2-fluorophenoxymethyl) phenyl] piperidine, serotonin and norepinephrine reuptake inhibitors; preparation procedure; pharmaceutical composition that includes them; and its use to treat neuropathic pain, fibromyalgia, depressive disorder and obesity among others.
AR084216A1 (en) COMPOSITIONS AND METHODS TO TREAT CANCER USING A PI3K INHIBITOR AND MEK INHIBITOR, KIT